Similar articles

• Lasofoxifene in postmenopausal women with osteoporosis.

  Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Cummings SR, et al. N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. N Engl J Med. 2010. PMID: 20181970 Clinical Trial.
• Another selective estrogen-receptor modulator for osteoporosis.

  Becker C. Becker C. N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847. N Engl J Med. 2010. PMID: 20181977 No abstract available.
• Lasofoxifene for postmenopausal women with osteoporosis.

  Katzeff BS. Katzeff BS. N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9. N Engl J Med. 2010. PMID: 20568309 No abstract available.
• [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

  Maeda T, Ke HZ, Simmons H, Thompson D. Maeda T, et al. Clin Calcium. 2004 Oct;14(10):85-93. Clin Calcium. 2004. PMID: 15577137 Review. Japanese.
• Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

  Peterson GM, Naunton M, Tichelaar LK, Gennari L. Peterson GM, et al. Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5. Ann Pharmacother. 2011. PMID: 21467260 Review.